Italia markets open in 4 hours 11 minutes

Basilea Pharmaceutica AG (0QNA.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
41,80+0,75 (+1,84%)
Alla chiusura: 06:15PM BST
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Basilea announces Zevtera® (ceftobiprole) marketing authorization in Brazil

    Basel/Allschwil, Switzerland, July 12, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that its distribution partner for Latin America, Knight Therapeutics Inc. (“Knight”, TSX: GUD), has received a marketing authorization from the Agência Nacional de Vigilância Sanitária (Anvisa) in Brazil for the broad-spectrum, anti-MRSA (methicillin-resistant Staphylococcus aureus) antibiotic Zevtera® (ceftobiprole). Zevtera is indicated for the treatm

  • GlobeNewswire

    Basilea announces positive results of phase 3 ERADICATE study with ceftobiprole in Staphylococcus aureus bacteremia (SAB)

    Ceftobiprole met primary and secondary efficacy endpoints Basilea plans to submit a New Drug Application (NDA) in the U.S. around year end 2022 Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, June 28, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today positive topline results for the phase 3 ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcu

  • GlobeNewswire

    Basilea reports progress on the implementation of its strategy to focus on anti-infectives

    ERADICATE phase 3 study exploring ceftobiprole for the treatment of patients with Staphylococcus aureus bacteremia (SAB) expected to report results shortlySeparate transactions for TTK/PLK1 inhibitor (BAL0891) and preclinical oncology projects expected to be concluded in H2 2022 No expansion of ongoing lisavanbulin clinical studies; exploring partnering opportunitiesDerazantinib rights to be transferred back to Merck & Co. by the end of 2022No material expenses related to oncology activities bey